Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of TAK-438 20 mg for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy
jRCT2080221748Phase 3
- Sponsor
- Takeda
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonoprazan in gastric ulcer, duodenal ulcer and Peptic ulcer disease (PUD), sponsored by Takeda.
02
Drugs
vonoprazan
03
Conditions
gastric ulcerduodenal ulcerPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT2080221748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221748.